Brief: Prelude Therapeutics Announces Second Quarter 2023 Financial Results And Provides Corporate Update
03/08/2023 14:51
Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES SECOND QUARTER 2023
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* PRELUDE THERAPEUTICS INC Q2 LOSS PER SHARE $0.54
* PRELUDE THERAPEUTICS INC - RECENT EQUITY FINANCING EXTENDS
CASH
RUNWAY INTO 2026
Source text for Eikon: ID:nGNXbZJMsC
Further company coverage: PRLD.O
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview